Monitor patient enrollment progress and any interim data releases. The Phase IIb readout is the next major catalyst; timeline not specified. Given the micro-cap status and historical volatility, position sizing should be conservative.
Price Chart
Executive Summary
SciSparc subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, a cannabinoid-based treatment for Tourette Syndrome. The trial builds on Phase IIa data showing 21% average tic reduction. This is a positive but early-stage milestone for a micro-cap biotech.
Key Facts
- NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110 in Tourette Syndrome.
- Phase IIa study showed an average tic reduction of 21% across participants.
- Phase IIb is a randomized, double-blind, placebo-controlled, cross-over trial with primary endpoint at weeks 12 and 26.
- Additional trial sites include Yale Child Study Center and Tel Aviv Sourasky Medical Center.
Financial Impact
No financial data provided; SciSparc market cap is approximately $3M.
Risk Factors
- Clinical trial failure or disappointing efficacy/safety results.
- Regulatory and enrollment delays.
- Potential dilution to fund ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327736 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $0.7920 (+38.58%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $0.7920 (−27.34%) |
Oct 22, 2026 5d ago | Press Release | $1.20 | awaiting T+5 | — | $0.7920 (−34.00%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $0.7920 (+60.40%) |
Oct 15, 2026 12d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.7920 (−60.40%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $0.7920 (−60.40%) |
Oct 7, 2026 20d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $0.7920 (−82.93%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $0.7920 (+82.59%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $0.7920 (−85.31%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $0.7920 (−84.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers